NOVELTY - An isolated nucleic acid (I) comprising at least 80 % sequence identity to a nucleotide sequence that encodes a polypeptide, given in the specification, is new.    USE - (I) Is used to recombinantly produce a PRO polypeptide. The Pro polypeptide is used to: (i) detect a PRO polypeptide in a sample; (ii) link a bioactive molecule to a cell expressing a PRO polypeptide; (iii) modulate a biological activity of a cell expressing a specific PRO polypeptide; (iv) stimulate the release of tumor necrosis factor (TNF)alpha from human blood; (v) modulate the uptake of glucose or free fatty acid (FFA) by skeletal muscle cells; (vi) stimulate the proliferation or differentiation of chondrocytes cells; (vii) modulate the uptake of glucose or FFA by adipocyte cells; (viii) stimulate the proliferation of or gene expression in pericyte cells; (ix) stimulate the release of proteoglycans from cartilage; (x) stimulate the proliferation of inner ear utricular supporting cells; (xi) stimulate the proliferation of T-lymphocyte cells; (xii) stimulate the release of a cytokine from peripheral blood mononuclear cells (PBMC); (xiii) inhibit the binding of A-peptide to factor VIIA; (xiv) inhibit the differentiation of adipocytes cells; (xv) stimulate the proliferation of endothelial cells; and (xvi) detect the presence of a tumor in a mammal (all claimed). The methods and compositions of the present invention are useful for the diagnosis, prevention and/or treatment of tumors, such as lung, colon, breast, prostate, rectal, cervical and liver tumors. The PRO polypeptides are also useful as molecular weight markers, or for chromosome identification. The PRO genes are useful as hybridization probes, or for screening libraries of human cDNA, genomic DNA or mRNA. The PRO genes may also be used in gene therapy, particularly for replacing a defective gene.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:    (1) an isolated nucleic acid comprising the full length coding sequence of the DNA deposited under one of several American Type Culture Collection (ATCC) accession numbers, given in the specification;    (2) a vector comprising (I);    (3) a host cell comprising (2);    (4) producing a PRO polypeptide;    (5) an isolated PRO polypeptide 80 % identical to one of several amino acid sequences, given in the specification, and encoded by (1);    (6) a chimeric molecule comprising (5);    (7) an antibody that specifically binds (5);    (8) an isolated extracellular domain of a PRO polypeptide;    (9) an isolated PRO polypeptide lacking its associated signal peptide;    (10) an isolated polypeptide having 80 % identity to (8) with or lacking its associated signal peptide, or to (9), both comprising one of several amino acid sequences, given in the specification;    (11) an isolated nucleic acid 80 % identical to a sequence encoding (10);    (12) detecting a specific PRO polypeptide, given in the specification, in a sample by contacting the sample with another different specific PRO polypeptide, given in the specification, and determining the formation of a PRO polypeptide conjugate in the sample;    (13) linking a bioactive molecule to a cell expressing a specific PRO polypeptide, given in the specification, by contacting the cell with another different specific PRO polypeptide, given in the specification, that is bound to the bioactive molecule and allowing the PRO polypeptides to bind;    (14) modulating a biological activity of a cell expressing a specific PRO polypeptide, given in the specification, by contacting the cell with another different specific PRO polypeptide, given in the specification, or an anti-PRO polypeptide antibody;    (15) stimulating the release of tumor necrosis factor (TNF)alpha from human blood by contacting the blood with a PRO polypeptide, given in the specification;    (16) modulating the uptake of glucose or free fatty acid (FFA) by skeletal muscle cells, comprising contacting the cells with a PRO polypeptide, given in the specification;    (17) stimulating the proliferation or differentiation of chondrocytes cells, by contacting the cells with a PRO polypeptide, given in the specification;    (18) modulating the uptake of glucose or FFA by adipocyte cells, by contacting the cells with a PRO polypeptide;    (19) stimulating the proliferation of or gene expression in pericyte cells, by contacting the cells with a PRO polypeptide;    (20) stimulating the release of proteoglycans from cartilage, by contacting the cartilage with a PRO polypeptide;    (21) stimulating the proliferation of inner ear utricular supporting cells, by contacting the cells with a PRO polypeptide;    (22) stimulating the proliferation of T-lymphocyte cells, by contacting the cells with a PRO polypeptide;    (23) stimulating the release of a cytokine from peripheral blood mononuclear cells (PBMC), by contacting the cells with a PRO polypeptide;    (24) inhibiting the binding of A-peptide to factor VIIA, by contacting a composition comprising the A-peptide and the factor VIIA with a PRO polypeptide;    (25) inhibiting the differentiation of adipocytes cells, by contacting the cells with a PRO polypeptide;    (26) stimulating the proliferation of endothelial cells, by contacting the cells with a PRO polypeptide;    (27) detecting the presence of a tumor in a mammal, by comparing the level of expression of any of the PRO polypeptides given in the specification in a test sample of cells taken from the mammal, and a control sample of normal cells of the same type, where a higher level of expression of the PRO polypeptide in the test sample compared to the control sample indicates the presence of the tumor in the mammal; and    (28) an oligonucleotide probe derived from a nucleotide sequence, given in the specification.